 Follicular lymphoma (FL) is highly associated with the molecular rearrangement BCL2/IGH.     ///    A real-time (PCR) for a real life?? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice..     ///    "Advanced clinical stage (III and IV) and microscopic BM involvement were significantly associated with higher numbers of BCL2/IGH in PB (p < 0.05) and in BM (p = 0.05), regardless all or newly diagnosed patients were evaluated. "    ///    "Although BCL2/IGH has been studied many times in follicular lymphoma, its real clinical value remains controversial. "    ///    High pretreatment burden of BCL2/IGH was associated with significantly shorter progression-free survival.     ///    "Pretreatment numbers of BCL2/IGH varied in wide ranges, with a median of 2947 (range, 0-1,261,013) copies/10(6) cellular equivalent in peripheral blood (PB) and 4650 copies/10(6) cellular equivalent (range, 1-1,056,813) in bone marrow (BM), the difference between PB and BM was significant (p?= 0.006). "    ///    "In conclusion, pretreatment quantity of BCL2/IGH in PB or BM seems to mirror the extent of disease and can provide an auxiliary prognostic parameter in FL. "    ///    "Pretreatment of BCL2/IGH quantities were correlated to clinical parameters (e.g., age, stage, sex, lactate dehydrogenase, B symptoms, grade, bulky disease, chemotherapy regimen) and to progression free-survival. "